At KweHealth, our mission is to transform regenerative medicine through science, technology, and responsibility. At the heart of our organization lies a commitment to developing a scalable manufacturing platform for perinatal-derived therapeutics—with exosomes at the core and complementary cell therapies alongside. We are tackling the critical challenges that have slowed the adoption of legitimate regenerative biotherapeutics: the complexity of biological systems, safety concerns, manufacturing scalability, regulatory barriers, and the proliferation of untested, unverified treatments that jeopardize patient safety and undermine the credibility of the field.

Our approach is built on rigorous science and measurable evidence. We integrate biomarker-driven analytics, AI, and advanced characterization technologies to establish the safety and efficacy of our products across specific patient populations and disease backgrounds. By leveraging connected devices, wearables, and mobile platforms, we also capture real-world data that validates therapeutic outcomes—ensuring our treatments are not only innovative but also proven, safe, and trustworthy.

Beyond our own pipeline, we are committed to empowering researchers and clinicians. We provide support for IND and IRB submissions, case reporting, CMC strategy, and regulatory consultations, alongside advanced analytical services. This enables our collaborators to bring forward therapies that meet the highest scientific and ethical standards, preserving the integrity of regenerative medicine while accelerating its clinical translation.

Looking ahead, we envision a future where regenerative medicine is defined by patient-centered innovation, robust data, and collaborative ecosystems. By combining advanced therapeutics with a culture of evidence, transparency, and responsibility, KweHealth is charting a path toward safer, more effective treatments—and a brighter future for patients worldwide.

— Dr. Mercedes F. Kweh, Founder & CEO